Hypoallergenic (Cosmetics Label Claim) - US, EU & South Korea

Issuer

{
 "EU": "European Commission (DG GROW), via the Working Group on Cosmetic Products / Sub-Working Group on Claims - an advisory group, not a legislative body; the Technical Document is explicitly stated to be non-binding and not an official Commission position.",
 "KR": "Ministry of Food and Drug Safety (MFDS).",
 "US": "U.S. Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition - but FDA issues no current standard, only informal consumer guidance."
}

Definition

"Hypoallergenic" on a cosmetic label is a manufacturer claim that a product has been formulated to produce fewer or milder allergic reactions than comparable products. It is not a certification mark, not a pass/fail test result, and - except for non-binding EU guidance - not tied to any legal definition. Meaning and evidentiary weight differ sharply by jurisdiction:

Guarantees

{
 "EU": "Under the non-binding Annex IV criteria: the product should be designed/formulated to minimize allergenic potential, and should avoid known allergens/sensitizer precursors - specifically substances or mixtures identified as skin sensitizers by the SCCS (Scientific Committee on Consumer Safety) or other official risk-assessment bodies. The claim must also meet the general common criteria of Regulation (EU) No 655/2013 (truthfulness, evidential support, honesty, fairness, informed decision-making). Because the document is guidance rather than law, there is no enforcement mechanism beyond the general false/misleading-claim provisions of Regulation (EC) 1223/2009 Art. 20.",
 "KR": "Only the general duty under Cosmetics Act Art. 14: any labeling/advertising claim capable of misleading consumers, including 'low-irritation'/'hypoallergenic'-type claims, must be backed by evidence on file - human-use test data (인체 적용시험 자료), non-human/in-vitro data (인체 외 시험 자료), or equivalent survey data gathered with sound sampling/statistical methodology - producible to MFDS on request. There is no minimum formulation standard or allergen-avoidance list specific to the word 'hypoallergenic' itself.",
 "US": "Nothing. FDA states in its own consumer guidance: \"There are no Federal standards or definitions that govern the use of the term 'hypoallergenic.' The term means whatever a particular company wants it to mean.\" Manufacturers need not submit substantiation to FDA to use the word."
}

Scope level

{
 "EU": "Per-product / per-SKU label claim, assessed against the specific formulation of that product; not a company-wide or brand-wide certification.",
 "KR": "Per-product / per-claim substantiation file, held by the responsible manufacturer/importer, not a public per-product certification.",
 "US": "N/A - no operative standard, so no scope to define."
}

Jurisdiction

{
 "EU": "European Union, all 27 Member States (cosmetics regulated under Regulation (EC) No 1223/2009 as recast).",
 "KR": "Republic of Korea, national (Ministry of Food and Drug Safety, MFDS / 식품의약품안전처, under the Cosmetics Act 화장품법).",
 "US": "Federal (FDA, cosmetics regulated under the FD&C Act and Fair Packaging and Labeling Act). No state-level definition identified."
}

Change history

[
 {
  "date": "1975",
  "event": "US FDA proposes a binding rule at 21 CFR 701.20 that would have required cosmetics labeled 'hypoallergenic' to show, via comparative testing, a materially lower incidence of adverse reactions than non-hypoallergenic products.",
  "jurisdiction": "US"
 },
 {
  "date": "1977 or 1979 (sources conflict)",
  "event": "Almay, Inc. and Clinique Laboratories, Inc. successfully challenge the rule; the U.S. Court of Appeals for the D.C. Circuit vacates it, holding FDA had not adequately supported its interpretation of consumer understanding of the term. FDA never reissued a rule. Citation is reported inconsistently across secondary sources: one gives 'Almay, Inc. v. Califano, 569 F.2d 674 (D.C. Cir. 1977)'; another gives 'Almay Inc. v. Califano, 613 F.2d 1070 (D.C. Cir. 1979)'. Both values are kept here unresolved rather than averaged, since the underlying court opinion could not be directly retrieved to adjudicate.",
  "jurisdiction": "US"
 },
 {
  "date": "2013-07",
  "event": "EU adopts Commission Regulation (EU) No 655/2013 laying down common criteria for the justification of cosmetic claims generally (truthfulness, evidential support, honesty, fairness, informed decision-making, compliance with law).",
  "jurisdiction": "EU"
 },
 {
  "date": "2011-08",
  "event": "Korea's Cosmetics Act undergoes comprehensive amendment introducing the labeling/advertising claim-substantiation system later detailed in Art. 14.",
  "jurisdiction": "KR"
 },
 {
  "date": "2017-07-03",
  "event": "European Commission's Working Group on Cosmetic Products adds Annex III ('free from' claims) and Annex IV ('hypoallergenic' claims) to the Technical Document on Cosmetic Claims.",
  "jurisdiction": "EU"
 },
 {
  "date": "2019-07-01",
  "event": "Annex III and Annex IV provisions of the EU Technical Document become applicable across Member States, after a two-year transition period.",
  "jurisdiction": "EU"
 },
 {
  "date": "2020-09-04",
  "event": "MFDS Notice No. 2020-80, '화장품 표시·광고 실증에 관한 규정' (Regulation on Substantiation of Cosmetics Labeling and Advertising), takes effect in Korea, formalizing general evidence requirements applicable to any claim including hypoallergenic-type wording.",
  "jurisdiction": "KR"
 }
]

Effective date

{
 "EU": "Annex IV adopted/added 2017-07-03; its provisions became applicable across the EU on 2019-07-01 after a two-year transition.",
 "KR": "MFDS Notice No. 2020-80 effective 2020-09-04 (general substantiation duty; not hypoallergenic-specific).",
 "US": "1975-XX-XX proposed (21 CFR 701.20); struck down by the D.C. Circuit - sources disagree on the exact date/citation (see change_history). No rule has been in effect since. FDA's current consumer guidance page restates that no federal standard exists but is undated on the page itself as fetched."
}

Registry lookup

{
 "EU": "None. The Technical Document is guidance text, not tied to any claims registry; no EU-wide public list of products approved to use the term exists.",
 "KR": "None public. Substantiation dossiers required under Cosmetics Act Art. 14 are retained by the company and produced to MFDS only on request/audit - not published as a searchable registry.",
 "US": "None. FDA maintains no database of 'hypoallergenic' products or claims.",
 "note": "This is not published anywhere as a lookup system in any of the three jurisdictions; treat as confirmed absence, not a gap in research."
}

Standard version

{
 "EU": "European Commission 'Technical Document on Cosmetic Claims,' Annex IV ('Hypoallergenicity claims') - non-binding guidance issued by the Sub-Working Group on Claims under the Working Group on Cosmetic Products, elaborating the common criteria in Commission Regulation (EU) No 655/2013. Annexes III and IV were added to the document on 3 July 2017.",
 "KR": "No claim-specific standard exists for '저자극'/'하이포알러제닉' (hypoallergenic). It falls under the general claim-substantiation regime: Cosmetics Act (화장품법) Art. 14, Enforcement Rule (시행규칙) Art. 23, and MFDS Notice No. 2020-80 '화장품 표시·광고 실증에 관한 규정' (Regulation on Substantiation of Cosmetics Labeling and Advertising).",
 "US": "None currently in force. FDA proposed a binding rule at 21 CFR 701.20 in 1975; it was vacated by the courts and never reissued. No successor rule or guidance defines the term."
}

Identifier format

{
 "value": "Not applicable / not published. Unlike certification marks (e.g., organic or dermatologist-tested seals issued by named certifiers), no jurisdiction studied issues a certificate number, registration ID, or standardized identifier for a 'hypoallergenic' claim. There is nothing to format."
}

Does not guarantee

{
 "EU": "The EU guidance explicitly notes 'hypoallergenic' claims 'should not give the impression that they guarantee a complete absence of risk of an allergic reaction, as no products can guarantee that.' Also does not guarantee compliance is checked pre-market - it is enforced only reactively (post-market surveillance / market-surveillance authority challenge), and the guidance itself is not judicially binding.",
 "KR": "Does not guarantee any specific irritation threshold, patch-test pass rate, or ingredient exclusion list - only that some form of evidence exists in the company's file, of a type and rigor MFDS considers adequate if it ever audits the claim.",
 "US": "No guarantee of any kind - the term is unregulated and unsubstantiated by requirement.",
 "all_jurisdictions": "In none of the three jurisdictions does 'hypoallergenic' guarantee zero risk of an allergic reaction for any individual user, guarantee the product is allergen-free, guarantee independent third-party testing, or confer a certification mark/registration number."
}

Editor note coverage

Per editor request, US/EU/KR differences are covered above for every field where published information exists. No jurisdiction was found to publish a quantitative allergy-reduction threshold (e.g., '% fewer reactions') for this claim; where a value is not published, that is stated directly rather than inferred.

All research records · Corrections: see our corrections policy.